MXPA03005937A - Compuestos farmaceuticamente activos. - Google Patents
Compuestos farmaceuticamente activos.Info
- Publication number
- MXPA03005937A MXPA03005937A MXPA03005937A MXPA03005937A MXPA03005937A MX PA03005937 A MXPA03005937 A MX PA03005937A MX PA03005937 A MXPA03005937 A MX PA03005937A MX PA03005937 A MXPA03005937 A MX PA03005937A MX PA03005937 A MXPA03005937 A MX PA03005937A
- Authority
- MX
- Mexico
- Prior art keywords
- cyclic guanosine
- phosphodiesterase inhibitors
- monophosphate phosphodiesterase
- monophosphate
- guanosine
- Prior art date
Links
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 title abstract 3
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 125000004122 cyclic group Chemical group 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 abstract 1
- 101150098694 PDE5A gene Proteins 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0106661.2A GB0106661D0 (en) | 2001-03-16 | 2001-03-16 | Pharmaceutically active compounds |
| PCT/IB2002/000659 WO2002074774A1 (en) | 2001-03-16 | 2002-03-04 | Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03005937A true MXPA03005937A (es) | 2003-09-10 |
Family
ID=9910932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03005937A MXPA03005937A (es) | 2001-03-16 | 2002-03-04 | Compuestos farmaceuticamente activos. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1368352B1 (enExample) |
| JP (1) | JP2004523585A (enExample) |
| AT (1) | ATE283856T1 (enExample) |
| BR (1) | BR0208154A (enExample) |
| CA (1) | CA2439528A1 (enExample) |
| DE (1) | DE60202134T2 (enExample) |
| ES (1) | ES2231667T3 (enExample) |
| GB (1) | GB0106661D0 (enExample) |
| MX (1) | MXPA03005937A (enExample) |
| WO (1) | WO2002074774A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60237425D1 (de) * | 2002-03-28 | 2010-10-07 | Univerzita Palackeho V Olomouc | PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE60332387D1 (de) | 2002-12-13 | 2010-06-10 | Warner Lambert Co | Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege |
| CN100374441C (zh) * | 2003-06-06 | 2008-03-12 | 天津倍方科技发展有限公司 | 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途 |
| JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体 |
| BRPI0412259B1 (pt) | 2003-07-22 | 2019-08-20 | Astex Therapeutics Limited | Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica |
| WO2005028480A2 (en) * | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| US7485637B2 (en) | 2005-01-04 | 2009-02-03 | Hoffmann-La Roche Inc. | Benzoyl-tetrahydropiperidine derivatives |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| ES2334578T3 (es) | 2005-02-07 | 2010-03-12 | F. Hoffmann-La Roche Ag | Fenil-metanonas sustituidas por heterociclo como inhibidores del transportador 1 de la glicina. |
| KR20080016531A (ko) * | 2005-02-18 | 2008-02-21 | 서피스 로직스, 인크. | 약동학적으로 개선된 화합물 |
| JP2009515984A (ja) | 2005-11-15 | 2009-04-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なアザインダゾール |
| EP1951668B1 (en) * | 2005-11-16 | 2010-04-14 | F.Hoffmann-La Roche Ag | Novel process for the preparation of thoc |
| CN101563348B (zh) * | 2006-12-21 | 2011-08-24 | 上海特化医药科技有限公司 | 西地那非的制备方法及其中间体 |
| EP2156833B1 (en) * | 2007-05-11 | 2011-11-30 | Santen Pharmaceutical Co., Ltd | Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient |
| JP5498392B2 (ja) | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| WO2010026214A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
| JP2012513464A (ja) | 2008-12-23 | 2012-06-14 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | ホスホジエステラーゼ阻害剤及びその使用 |
| DK2414363T3 (da) | 2009-03-31 | 2014-01-27 | Boehringer Ingelheim Int | 1-heterocyklyl-1,5-dihydro-pyrazol[3,4-d]pyrimidin-4-on-derivater og anvendelse af disse som PDE9A-modulatorer. |
| TWI393578B (zh) | 2009-07-07 | 2013-04-21 | Shl Group Ab | 注射裝置 |
| WO2012020022A1 (en) | 2010-08-12 | 2012-02-16 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| WO2012143144A1 (en) * | 2011-04-21 | 2012-10-26 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
| WO2012143143A1 (en) | 2011-04-21 | 2012-10-26 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| MX2014011115A (es) | 2012-03-16 | 2015-03-13 | Axikin Pharmaceuticals Inc | Inhibidores de 3,5-diaminopirazol cinasa. |
| WO2014060112A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| US10000482B2 (en) | 2012-10-19 | 2018-06-19 | Origenis Gmbh | Kinase inhibitors |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| WO2015091428A1 (en) * | 2013-12-20 | 2015-06-25 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| MY191736A (en) | 2014-12-23 | 2022-07-13 | Axikin Pharmaceuticals Inc | 3,5-diaminopyrazole kinase inhibitors |
| AU2016355854B2 (en) * | 2015-11-16 | 2021-05-06 | Topadur Pharma Ag | 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1493685A (en) * | 1970-12-15 | 1977-11-30 | May & Baker Ltd | 8-azapurinones |
| GB8817651D0 (en) * | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
| US6225315B1 (en) * | 1998-11-30 | 2001-05-01 | Pfizer Inc | Method of treating nitrate-induced tolerance |
| EA200200240A1 (ru) * | 1999-10-11 | 2002-10-31 | Пфайзер Инк. | 5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ |
-
2001
- 2001-03-16 GB GBGB0106661.2A patent/GB0106661D0/en not_active Ceased
-
2002
- 2002-03-04 AT AT02701497T patent/ATE283856T1/de not_active IP Right Cessation
- 2002-03-04 EP EP02701497A patent/EP1368352B1/en not_active Expired - Lifetime
- 2002-03-04 WO PCT/IB2002/000659 patent/WO2002074774A1/en not_active Ceased
- 2002-03-04 DE DE60202134T patent/DE60202134T2/de not_active Expired - Fee Related
- 2002-03-04 BR BR0208154-7A patent/BR0208154A/pt not_active IP Right Cessation
- 2002-03-04 ES ES02701497T patent/ES2231667T3/es not_active Expired - Lifetime
- 2002-03-04 CA CA002439528A patent/CA2439528A1/en not_active Abandoned
- 2002-03-04 MX MXPA03005937A patent/MXPA03005937A/es unknown
- 2002-03-04 JP JP2002573783A patent/JP2004523585A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1368352A1 (en) | 2003-12-10 |
| ATE283856T1 (de) | 2004-12-15 |
| CA2439528A1 (en) | 2002-09-26 |
| DE60202134D1 (en) | 2005-01-05 |
| GB0106661D0 (en) | 2001-05-09 |
| EP1368352B1 (en) | 2004-12-01 |
| DE60202134T2 (de) | 2005-11-24 |
| ES2231667T3 (es) | 2005-05-16 |
| JP2004523585A (ja) | 2004-08-05 |
| BR0208154A (pt) | 2004-03-02 |
| WO2002074774A1 (en) | 2002-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03005937A (es) | Compuestos farmaceuticamente activos. | |
| CA2287552A1 (en) | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction | |
| AU5995699A (en) | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction | |
| AP2002002455A0 (en) | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors. | |
| MXPA03006310A (es) | Compuestos farmaceuticamente activos. | |
| ATE298753T1 (de) | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung der sexuellen dysfunktion | |
| CA2322900A1 (en) | 2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors | |
| BR0004779A (pt) | Compostos farmaceuticamente ativos | |
| MY132106A (en) | New pyridazin-3(2h)-one derivatives | |
| WO2002064590A3 (en) | Carboline derivatives | |
| MY135909A (en) | Treatment of pulmonary hypertension | |
| MY140674A (en) | New crystalline form of a triazolo(4,5-d)pyrimidine compound | |
| BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
| WO2002064591A3 (en) | Carboline derivatives | |
| CA2413510A1 (en) | Condensed pyrazindione derivatives | |
| WO2002079203A8 (en) | Imidazo-triazine derivatives as pde 5 inhibitors | |
| CA2412596A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
| AP2002002462A0 (en) | Pharmaceutically active compounds. | |
| EP1241170A3 (en) | Pyrazolopyrimidine derivatives | |
| DE60226970D1 (de) | Pyrazinoä1',2':1,6ü-pyridoä3,4-bü indole-1,4-dionderivate | |
| ECSP003706A (es) | Compuestos farmaceuticamente activos |